Brain Imaging, Genetics and the Prevention of Alzheimer’s Disease

What will it take to find and support the approval and availability of an Alzheimer’s prevention therapy before 2025? In this presentation, Eric Reiman will describe the strategy he and his Alzheimer’s Prevention Initiative (API) colleagues have introduced to accelerate the evaluation of prevention therapies in persons who, based on their genetic background or biomarker findings are at increased risk for Alzheimer’s disease. He will discuss how the study of mutation carriers and non-carriers from the world’s largest early-onset autosomal dominant Alzheimer’s disease kindred, the study of persons at three levels of genetic risk for developing Alzheimer’s at older ages, and other studies have enabled them to detect and track Alzheimer’s starting many years before the onset of symptoms, launch a new era of Alzheimer’s prevention research, and contribute to the scientific understanding of this terrible disorder. Dr. Reiman is a recipient of the Potamkin Prize, which has been described as the Nobel Prize in Alzheimer’s research.

Learn more about Dr. Reiman

Continuing Medical Education Credit

Continuing Medical Education (CME) credit is being offered for 2018 - 2019 Genetics and Genomics Grand Rounds series through the University of Arizona College of Medicine - Tucson.

The University of Arizona College of Medicine – Tucson is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Arizona College of Medicine – Tucson designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

2018 - 2019 Genetics and Genomics Grand Rounds Learning Objectives

1. Integrate advances in genetic diagnosis and treatment into the day-to-day practices of research and clinical care.
2. Order appropriate diagnostic evaluations for patients with hereditary medical conditions.

All Faculty, CME Planning Committee Members, and the CME Office Reviewers have disclosed that they do not have any relevant financial relationships with commercial interests that would constitute a conflict of interest concerning this CME activity.

Presented By